Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
Status:
Terminated
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This is a phase 2 study evaluating medical treatment before surgery in HER2-amplified early
breast cancer patients. Patients receive chemotherapy with HER2-targeted antibodies and are
randomised to receive the checkpoint inhibitor atezolizumab or not.